In April 2026, Boehringer Ingelheim crossed a threshold that veterinary experts and livestock farmers across Eastern Africa have been waiting for: the company officially joined the AgResults Foot and Mouth Disease Vaccine Challenge, bringing a regionally tailored quadrivalent vaccine to Ethiopia, Uganda and Rwanda. For millions of smallholder farmers whose livelihoods depend on healthy cattle herds, this represents something concrete—a new tool to fight one of the region's most economically destructive animal diseases.
Foot and Mouth Disease has long haunted Eastern Africa's livestock sector. The virus devastates cattle productivity, blocks trade across borders, and drains the incomes of farming families already operating on thin margins. In a region where livestock production anchors rural economies and feeds millions, that ripple effect matters enormously. The AgResults FMD Vaccine Challenge Project, managed by GALVmed and launched in February 2020, was designed precisely to address this gap. With US$17.34 million committed over eight years, it functions as a pay-for-results competition—a novel approach that rewards vaccine manufacturers not just for meeting standards, but for actually reaching farmers and improving outcomes on the ground.
Boehringer Ingelheim's entry came only after the company met strict Target Product Profile requirements and won approval from the project's judging panel. The competition unfolds in two phases. The first, focused on vaccine development, pushed manufacturers to engineer quadrivalent vaccines—formulations that protect against multiple FMD virus strains—tailored to the specific disease variants and farming systems found in Eastern Africa, not generic global solutions. The second phase, which began in October 2024, shifted gears entirely. Rather than just rewarding laboratory success, it introduced a vaccine distribution cost-share mechanism designed to drive real-world adoption. By subsidizing vaccine costs for both public and private sector buyers, the program tackles the fundamental barrier that keeps many farmers from accessing better protection: affordability.
"Initiatives like this play an important role in supporting access to effective FMD vaccines for both public and private sector stakeholders in the region," said Tamer Saddec, Boehringer Ingelheim's Regional VPH Commercial Manager. His observation captures the project's essential insight—that innovation without access is merely academic.
GALVmed's Project Manager Lead, Nina Henning, sees Boehringer Ingelheim's participation as a turning point. "Their expertise and dedication are crucial as we work towards a vaccine that can transform the livestock industry in Eastern Africa," she said. That transformation, if it materializes, would ripple outward. Reducing disease outbreaks strengthens herd health, which increases productivity, which creates more reliable income and food security for rural households. Wider vaccine access also improves market access for farmers, allowing them to trade livestock across borders with greater confidence.
The AgResults program itself—a global initiative using incentive-based approaches to spur private-sector innovation in agriculture—has proven that competition and clear financial rewards can accelerate solutions to agricultural problems that markets alone haven't solved. Parasto Hamidi, AgResults Secretariat Team Lead, noted that "the collaboration and innovation demonstrated in this project are paving the way for sustainable solutions to FMD."
What makes this milestone significant is not just the vaccine itself, but the mechanism behind it. By combining rigorous product standards, competitive incentives, and cost-sharing that makes vaccines accessible to farmers, the project addresses a problem that has persisted for years. For Eastern Africa's livestock sector and the millions who depend on it, that combination—innovation meeting affordability—may finally turn the tide.